Assessment of Dasatinib Versus Nilotinib as Upfront Therapy for Chronic Phase of Chronic Myeloid Leukemia in Qatar: A Cost-Effectiveness Analysis

by Ahmad Adel MSc, Dina Abushanab MSc (Pharm), Anas Hamad PhD, Mohammad Abdulla MD, Mohamed Izham PhD, Mohamed Yassin MD
Published 2021-04-01